JP6335800B2 - 末梢神経のIgG刺激性再ミエリン化法 - Google Patents

末梢神経のIgG刺激性再ミエリン化法 Download PDF

Info

Publication number
JP6335800B2
JP6335800B2 JP2014560045A JP2014560045A JP6335800B2 JP 6335800 B2 JP6335800 B2 JP 6335800B2 JP 2014560045 A JP2014560045 A JP 2014560045A JP 2014560045 A JP2014560045 A JP 2014560045A JP 6335800 B2 JP6335800 B2 JP 6335800B2
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
neuropathy
polyclonal igg
composition according
ivig
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2014560045A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015508824A5 (cg-RX-API-DMAC7.html
JP2015508824A (ja
Inventor
パトリック クエリー
パトリック クエリー
ネヴェナ ツェコヴァ
ネヴェナ ツェコヴァ
ハンス−ペーター ハルタング
ハンス−ペーター ハルタング
コリーナ ヘルマン
コリーナ ヘルマン
バージット マリア レイペルト
バージット マリア レイペルト
ハンス−ペーター シュワルツ
ハンス−ペーター シュワルツ
ハルトムット アーリッヒ
ハルトムット アーリッヒ
セバスチャン バンク
セバスチャン バンク
Original Assignee
バクスアルタ ゲーエムベーハー
バクスアルタ ゲーエムベーハー
バクスアルタ インコーポレイテッド
バクスアルタ インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by バクスアルタ ゲーエムベーハー, バクスアルタ ゲーエムベーハー, バクスアルタ インコーポレイテッド, バクスアルタ インコーポレイテッド filed Critical バクスアルタ ゲーエムベーハー
Publication of JP2015508824A publication Critical patent/JP2015508824A/ja
Publication of JP2015508824A5 publication Critical patent/JP2015508824A5/ja
Application granted granted Critical
Publication of JP6335800B2 publication Critical patent/JP6335800B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39516Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum from serum, plasma
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065Purification, fragmentation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
JP2014560045A 2012-02-29 2013-02-28 末梢神経のIgG刺激性再ミエリン化法 Active JP6335800B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261605117P 2012-02-29 2012-02-29
US61/605,117 2012-02-29
PCT/US2013/028350 WO2013130826A2 (en) 2012-02-29 2013-02-28 Igg stimulated remyelination of peripheral nerves

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017175330A Division JP6637934B2 (ja) 2012-02-29 2017-09-13 末梢神経のIgG刺激性再ミエリン化法

Publications (3)

Publication Number Publication Date
JP2015508824A JP2015508824A (ja) 2015-03-23
JP2015508824A5 JP2015508824A5 (cg-RX-API-DMAC7.html) 2016-04-14
JP6335800B2 true JP6335800B2 (ja) 2018-05-30

Family

ID=47884569

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2014560045A Active JP6335800B2 (ja) 2012-02-29 2013-02-28 末梢神経のIgG刺激性再ミエリン化法
JP2017175330A Active JP6637934B2 (ja) 2012-02-29 2017-09-13 末梢神経のIgG刺激性再ミエリン化法
JP2019183415A Active JP6979990B2 (ja) 2012-02-29 2019-10-04 末梢神経のIgG刺激性再ミエリン化法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2017175330A Active JP6637934B2 (ja) 2012-02-29 2017-09-13 末梢神経のIgG刺激性再ミエリン化法
JP2019183415A Active JP6979990B2 (ja) 2012-02-29 2019-10-04 末梢神経のIgG刺激性再ミエリン化法

Country Status (21)

Country Link
US (5) US8986670B2 (cg-RX-API-DMAC7.html)
EP (2) EP2820042B1 (cg-RX-API-DMAC7.html)
JP (3) JP6335800B2 (cg-RX-API-DMAC7.html)
KR (3) KR102170615B1 (cg-RX-API-DMAC7.html)
CN (4) CN104302666A (cg-RX-API-DMAC7.html)
AR (2) AR090211A1 (cg-RX-API-DMAC7.html)
AU (3) AU2013203088B2 (cg-RX-API-DMAC7.html)
BR (1) BR112014021240A2 (cg-RX-API-DMAC7.html)
DK (2) DK2820042T3 (cg-RX-API-DMAC7.html)
EA (2) EA032000B1 (cg-RX-API-DMAC7.html)
ES (2) ES2755056T3 (cg-RX-API-DMAC7.html)
FI (1) FI3590960T3 (cg-RX-API-DMAC7.html)
HK (1) HK1248534A1 (cg-RX-API-DMAC7.html)
IL (3) IL274512B2 (cg-RX-API-DMAC7.html)
MX (2) MX369444B (cg-RX-API-DMAC7.html)
NZ (1) NZ629867A (cg-RX-API-DMAC7.html)
PL (2) PL3590960T3 (cg-RX-API-DMAC7.html)
PT (2) PT3590960T (cg-RX-API-DMAC7.html)
SG (1) SG11201405302WA (cg-RX-API-DMAC7.html)
TW (3) TWI632158B (cg-RX-API-DMAC7.html)
WO (1) WO2013130826A2 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2820042T3 (da) * 2012-02-29 2019-10-28 Baxalta GmbH Igg-stimuleret remyelinisering af perifere nerver
US9690975B2 (en) * 2015-05-28 2017-06-27 Axogen Corporation Quantitative structural assay of a nerve graft
CN111655336A (zh) 2017-11-17 2020-09-11 纽约州立大学研究基金会 使用x射线微束辐射治疗受损周围神经的方法
US20220111012A1 (en) * 2019-01-07 2022-04-14 Mallinckrodt Ard Ip Unlimited Company Methods of promoting remyelination
WO2025005230A1 (ja) * 2023-06-30 2025-01-02 富士フイルム株式会社 神経炎症の細胞間相互作用を評価する方法

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE348942B (cg-RX-API-DMAC7.html) 1970-06-02 1972-09-18 Statens Bakteriologiska Labor
DK166763B1 (da) 1983-03-16 1993-07-12 Immuno Ag Immunoglobulin-g-holdig fraktion
AT376367B (de) 1983-03-16 1984-11-12 Immuno Ag Verfahren zur herstellung von therapeutisch verabreichbaren, in endbehaeltern abgefuellten plasmaderivaten
ATE36457T1 (de) 1983-05-02 1988-09-15 Immuno Ag Verfahren zur inaktivierung von vermehrungsfaehigen krankheitserregern.
AT389815B (de) 1984-03-09 1990-02-12 Immuno Ag Verfahren zur inaktivierung von vermehrungsfaehigen filtrierbaren krankheitserregern in blutprodukten
AT390560B (de) 1986-05-30 1990-05-25 Immuno Ag Verfahren zur inaktivierung von vermehrungsfaehigen filtrierbaren krankheitserregern
JP2871709B2 (ja) 1988-11-21 1999-03-17 住友製薬株式会社 免疫グロブリンg結合活性を有する新規な蛋白質プロテインh、該蛋白質をコードする遺伝子及び該蛋白質の製造法
US5177194A (en) 1990-02-01 1993-01-05 Baxter International, Inc. Process for purifying immune serum globulins
CA2089582A1 (en) * 1990-08-15 1992-02-16 Richard P. Bunge Autotransplantation of schwann cells to promote nervous system repair
AT402891B (de) 1991-06-20 1997-09-25 Immuno Ag Verfahren zur herstellung eines inaktivierten blutproduktes
WO1994013329A1 (de) 1992-12-16 1994-06-23 Immuno Aktiengesellschaft Verfahren zur herstellung eines virussicheren biologischen präparates
FR2706466B1 (fr) 1993-06-14 1995-08-25 Aetsrn Concentré d'immunoglobulines G à usage thérapeutique et procédé de production dudit concentré.
HRP940645A2 (en) 1993-10-06 1996-12-31 Immuno Ag Process for virus deactivation in the presence of polyalkylene glycol and the pharmaceutical preparation thus obtained
TW491855B (en) 1996-08-07 2002-06-21 Csl Ltd Purification of immunoglobulins
US5886154A (en) 1997-06-20 1999-03-23 Lebing; Wytold R. Chromatographic method for high yield purification and viral inactivation of antibodies
BR9911131A (pt) 1998-06-09 2001-03-06 Statens Seruminstitut Processo para produção de imunoglobulinas para administração intravenosa e outros produtos de imunoglobulina
SE0001128D0 (sv) 2000-03-30 2000-03-30 Amersham Pharm Biotech Ab A method of producing IgG
MXPA02011163A (es) * 2000-05-10 2004-08-19 Mayo Foundation Anticuerpos igm humanos con la capacidad de inducir remielinacion, y usos diagnosticos y terapeuticos de los mismos particularmente en el sistema nervioso central.
FR2824568B1 (fr) 2001-05-11 2004-04-09 Lab Francais Du Fractionnement Procede de preparation de concentres d'immunoglobulines humaines a usage therapeutique
JP2003070465A (ja) * 2001-08-31 2003-03-11 Keio Gijuku シュワン細胞の培養方法
RU2412721C2 (ru) 2003-01-24 2011-02-27 Элан Фармасьютикалз Инк. Применение ремиелинизирующего средства для стимуляции нервных клеток при демиелинизирующем заболевании
JP2008500959A (ja) 2004-01-30 2008-01-17 スオメン プナイネン リスティ ヴェリパルヴェル ウイルスについて安全な免疫グロブリンの製造方法
EP1718675B2 (en) 2004-02-27 2017-01-25 Octapharma AG A method of providing a purified, virus safe antibody preparation
GEP20135853B (en) * 2007-02-02 2013-06-25 Univ Pierre And Marie Curie Method of myelination and oligodendrocyte differentiation promotion
US7854703B2 (en) 2007-09-25 2010-12-21 Intel Corporation Peripheral neuropathy detection
CA2643496C (en) 2008-11-06 2015-02-03 Michael Fehlings The therapeutic use of igg as a neuroprotective agent
CN102021140B (zh) * 2009-09-18 2013-04-24 上海市第一人民医院 一种分离、纯化许旺细胞的方法
DK2820042T3 (da) * 2012-02-29 2019-10-28 Baxalta GmbH Igg-stimuleret remyelinisering af perifere nerver

Also Published As

Publication number Publication date
AU2013203088B2 (en) 2015-12-03
TW201736398A (zh) 2017-10-16
KR20220045087A (ko) 2022-04-12
US10494418B2 (en) 2019-12-03
SG11201405302WA (en) 2014-09-26
DK2820042T3 (da) 2019-10-28
FI3590960T3 (fi) 2023-04-25
ES2755056T3 (es) 2020-04-21
PT2820042T (pt) 2019-10-31
AU2018200026B2 (en) 2019-12-05
MX2014010387A (es) 2015-09-25
US20200216518A1 (en) 2020-07-09
JP6637934B2 (ja) 2020-01-29
AR117207A2 (es) 2021-07-21
BR112014021240A2 (pt) 2018-09-18
JP2020059705A (ja) 2020-04-16
TW201400502A (zh) 2014-01-01
IL234303B (en) 2020-09-30
NZ629867A (en) 2016-09-30
IL274512B2 (en) 2024-07-01
KR20140134690A (ko) 2014-11-24
AU2016201137A1 (en) 2016-03-10
PL3590960T3 (pl) 2023-07-17
WO2013130826A3 (en) 2013-12-05
CN109966488A (zh) 2019-07-05
PL2820042T3 (pl) 2020-03-31
IL274512A (en) 2020-06-30
EP3590960B1 (en) 2023-03-29
HK1206035A1 (en) 2015-12-31
US20180291087A1 (en) 2018-10-11
US8986670B2 (en) 2015-03-24
CN104302666A (zh) 2015-01-21
JP6979990B2 (ja) 2021-12-15
US20210300997A1 (en) 2021-09-30
CN107551269A (zh) 2018-01-09
US20150232536A1 (en) 2015-08-20
AU2016201137B2 (en) 2017-10-12
EA201892521A1 (ru) 2019-07-31
AR090211A1 (es) 2014-10-29
ES2943585T3 (es) 2023-06-14
TWI632158B (zh) 2018-08-11
AU2013203088A1 (en) 2013-09-19
MX369444B (es) 2019-11-08
MX2019012496A (es) 2020-01-20
IL277103B2 (en) 2025-07-01
EP3590960A1 (en) 2020-01-08
TWI700297B (zh) 2020-08-01
DK3590960T3 (da) 2023-04-24
WO2013130826A2 (en) 2013-09-06
KR102673154B1 (ko) 2024-06-05
HK1248534A1 (zh) 2018-10-19
KR20200126005A (ko) 2020-11-05
IL277103A (en) 2020-10-29
PT3590960T (pt) 2023-04-18
KR102170615B1 (ko) 2020-10-28
AU2018200026A1 (en) 2018-01-25
EP2820042A2 (en) 2015-01-07
EP2820042B1 (en) 2019-07-24
JP2015508824A (ja) 2015-03-23
EA201400966A1 (ru) 2014-12-30
CN110343171A (zh) 2019-10-18
TW201838654A (zh) 2018-11-01
JP2018030856A (ja) 2018-03-01
US9834593B2 (en) 2017-12-05
IL274512B1 (en) 2024-03-01
EA032000B1 (ru) 2019-03-29
US20130224150A1 (en) 2013-08-29
IL277103B1 (en) 2025-03-01

Similar Documents

Publication Publication Date Title
JP6979990B2 (ja) 末梢神経のIgG刺激性再ミエリン化法
US9775899B2 (en) Treating neurological disorders
HK40018190B (en) Igg stimulated remyelination of peripheral nerves
HK40018190A (en) Igg stimulated remyelination of peripheral nerves
HK1206035B (en) Igg stimulated remyelination of peripheral nerves
EA040995B1 (ru) Ремиелинизация периферических нервов, стимулированная igg

Legal Events

Date Code Title Description
RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20150421

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160226

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160226

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20160511

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20160608

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20160610

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20161207

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170303

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170316

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170614

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170815

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170913

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20170921

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180119

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180228

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20180302

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20180402

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20180501

R150 Certificate of patent or registration of utility model

Ref document number: 6335800

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250